Securities Antitrust Consumer Fraud Structured Finance Whistleblower/Qui Tam Corporate Governance Mergers & Acquisitions ERISA Healthcare Fraud
PartnersOf Counsel Associates Staff Attorneys All
M & A Investigations New Federal Securities Cases Current CasesSettlements & Class Notices Accolades
Our Institutional Monitoring Service Our ProcessReporting Custom Monitoring
Articles Press Releases Television
Contact Us Join a Class Action Report a Fraud

New Federal Securities Cases

Teva Pharmaceuticals, Inc.

A class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Teva Pharmaceutical Industries Ltd. ("Teva" or the "Company")(NYSE: TEVA) on behalf of all persons or entities who acquired Teva American Depository Shares ("ADSs") on the New York Stock Exchange ("NYSE") and/or common stock on the Tel Aviv Stock Exchange ("TASE") during the period from November 15, 2016 through August 2, 2017 ("Class Period"). The lawsuit seeks to recover damages for investors under the federal securities laws.

The lawsuit charges Teva and certain of its officers and/or directors with violations of the Securities Exchange Act of 1934. Teva develops, manufactures, markets, and distributes generic medicines. The lawsuit alleges that during the Class Period, defendants failed to disclose that the poor performance of its U.S. generics business resulted in Teva's recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting Teva's dividend by 75%.

Defendants disclosed, on August 3, 2017, a goodwill impairment charge of $6.1 billion in the second quarter of 2017, and lower than expected Q2 results attributed to the accelerated price erosion and decreased volume experienced in the U.S. generics business due to customer consolidation, greater competition, and delayed product launches. In reaction to these announcements, Teva shares dropped from closing prices of $31.25 per ADS on August 2, 2017, to a new 52-week low closing price $20.60 per ADS on August 4, 2017, on heavy two-day trading volume, damaging investors.

If you acquired Teva securities during the Class Period, you may, no later than October 23, 2017, request the court to appoint you lead plaintiff of the class. Although your ability to share in any recovery is not affected by the decision whether or not to seek appointment as a lead plaintiff, lead plaintiffs make important decisions that could affect the overall recovery for class members, including decisions concerning settlement.

If you are a current or former Teva shareholder and wish to obtain additional information, please fill out the contact form at the link below.

Investigation Contact Form

Teva Pharmaceutical Industries Ltd.


Ira M. Press

Kirby McInerney LLP | 825 Third Avenue | NYC 10022 | Tel. 212.371.6600 | Fax 212.751.2540

Attorney Advertising - Prior Results do not Guarantee a Similar Outcome

Law Firm Web Design by Business Edge